EX-VIVO PATIENT DERIVED XENOGRAFT STUDIES
PHENOVISTA HAS PARTNERED WITH CHAMPIONS ONCOLOGY TO PERFORM EX-VIVO STUDIES ON THEIR PATIENT DERIVED XENOGRAFT (PDX) MODELS. THE >1200 PDX MODELS REPRESENT A DIVERSE SET OF TUMOR TYPES WITH EXTENSIVE CLINICAL AND MOLECULAR CHARACTERIZATION. AT PHENOVISTA WE GENERATE 3D TUMOR FRAGMENTS FROM THE PDX TISSUE, FOR EVALUATION OF THERAPEUTIC TREATMENT CANDIDATES BY IMAGING.
RAPID IN VITRO ASSESSMENT OF DRUG TREATMENTS (SMALL MOLECULES, BIOLOGICS, IMMUNO-THERAPIES, COMBINATION STUDIES)
HIGHLY MULIPLEXED DETERMINATION OF CANDIDATE DRUGS AND DOSING FOR IN VIVO STUDIES
3D CULTURES PROVIDE BETTER PREDICTIVITY OF DRUG RESISTANCE
PDX STUDIES: SMALL MOLECULE TREATMENT

